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It is generally accepted that autologous saphenous
vein (SV) is the best conduit for infrainguinal revas-
cularization, particularly when the vein is of normal
size and free of sclerotic segments. However, many
studies have reported acceptable results with polyte-
trafluoroethylene (PTFE) grafts for femoropopliteal
bypass grafting, particularly in claudicants and when
the distal anastomosis is above the knee.1-6
Proponents of the preferential use of PTFE for
femoropopliteal bypass grafting cite the following
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Objectives: Although there are numerous reports comparing saphenous vein (SV) and
polytetrafluoroethylene (PTFE) with respect to the patency rates for femoropopliteal
bypass grafts, the clinical consequences of failed grafts are not as well described. This
study compares the outcomes of failed SV and PTFE grafts with a specific emphasis on
the degree of acute limb ischemia caused by graft occlusion.
Methods: Over a 6-year period, 718 infrainguinal revascularization procedures were per-
formed, of which 189 were femoropopliteal bypass grafts (SV, 108; PTFE, 81). Society
for Vascular Surgery/International Society for Cardiovascular Surgery (SVS/ISCVS)
standardized runoff scores were calculated from preoperative arteriograms. Clinical cat-
egories of acute limb ischemia resulting from graft occlusion were graded according to
SVS/ISCVS standards (I, viable; II, threatened; III, irreversible). Primary graft paten-
cy and limb salvage rates at 48 months were calculated according to the Kaplan-Meier
method.
Results: Patients were well matched for age, sex, and comorbidities. Chronic critical
ischemia was the operative indication in most cases (SV, 82%; PTFE, 80%; P = .85).
Runoff scores and preoperative ankle-brachial index measurements were similar for the
two groups (SV, 6.0 ± 2.5 [SD] and 0.51 ± 0.29; PTFE, 5.3 ± 2.8 and 0.45 ± 0.20; P
= .06 and P = .12). The distal anastomosis was made below the knee in 60% of SV grafts
and 16% of PTFE grafts (P < .001). Grade II ischemia was more likely to occur after
occlusion of PTFE grafts (78%) than after occlusion of SV grafts (21%; P = .001).
Emergency revascularization after graft occlusion was required for 28% of PTFE failures
but only 3% of SV graft failures (P < .001). Primary graft patency at 48 months was 58%
for SV grafts and 32% for PTFE grafts (P = .008). Limb salvage was achieved in 81% of
SV grafts but only 56% of PTFE grafts (P = .019).
Conclusions: Patients undergoing femoropopliteal bypass grafting with PTFE are at
greater risk of ischemic complications from graft occlusion and more frequently require
emergency limb revascularization as a result of graft occlusion than patients receiving SV
grafts. Graft patency and limb salvage are superior with SV in comparison with PTFE in
patients undergoing femoropopliteal bypass grafting. (J Vasc Surg 2000;32:498-505)
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advantages of this approach: decreased operative time,
lower morbidity from a more limited dissection, and
preservation of the SV for future revascularization.
Although the patency rates and relative advan-
tages of vein and PTFE femoropopliteal bypass grafts
have been well described, there is little emphasis in
these reports on the ischemic consequences that
occur after occlusion of vein and PTFE grafts.
Furthermore, reports of the degree of tibial runoff
quality frequently are very descriptive and lack objec-
tive scoring that would enable more meaningful
comparisons between groups. In 1997, revised
reporting standards for reports dealing with lower
extremity ischemia were published by the Joint
Council of the Society for Vascular Surgery and the
North American Chapter of the International Society
for Cardiovascular Surgery (SVS/ISCVS).7 In this
report, a scoring system is proposed that is based on
a “weighted” score for the major runoff vessels and
that assigns increasing numbers of points for pro-
gressive degrees of stenosis and occlusion. In addi-
tion, objective categories of acute limb ischemia and
viability are proposed; these are based on physical
and Doppler scan findings. The purpose of our study
was to compare the outcome of failed SV and PTFE
femoropopliteal bypass grafts with a specific empha-
sis on the degree of ischemia caused by graft occlu-
sion as described in the revised reporting standards.
MATERIALS AND METHODS
Over a 6-year period (1991-1997), 718 infrain-
guinal revascularization procedures were performed,
of which 189 were femoropopliteal bypass grafts.
Patients from two medical centers were included in
the study (University of Texas Southwestern Medical
Center, N = 170; William Beaumont Army Medical
Center, N = 19). Saphenous vein was used in 108 of
the cases and PTFE in the other 81. Vein patches and
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cuffs were not used on the distal anastomosis in the
PTFE group. In both centers, SV is the preferred
conduit, PTFE being generally reserved for those
patients in whom the SV has been previously har-
vested or is of poor quality. We define poor-quality
SV by a distended diameter of less than 4 mm, mul-
tiple sclerotic segments requiring more than one ve-
novenostomy, and duplex scanning findings of occlu-
sion. Small but patent veins on duplex scanning are
explored for direct verification before being excluded
for use. The diameter of the PTFE grafts was 6 mm
in 41% of the patients, 7 mm in 34%, 8 mm in 23%,
and 10 mm in 1%. Preoperative arteriograms were
scored to calculate the standardized runoff score
according to the SVS/ISCVS reporting standards.7
These scores range from 1 to 10, 1 assigned for an
entirely normal three-vessel runoff, and 10 assigned
for an isolated popliteal segment with all three tibial
arteries occluded throughout their lengths.
All patients were treated with aspirin periopera-
tively and received systemic heparin intraoperative
anticoagulation. Postoperative follow-up protocols
and treatment were the same at both institutions.
Postoperative anticoagulation was not used. Patients
were followed up every 6 months with physical exam-
ination and measurement of ankle-brachial index
(ABI). Onset of ischemic symptoms or a decrease in
the ABI of 0.10 or more prompted arteriographic
evaluation. Exceptions to routine arteriography for
confirmation of graft occlusion were as follows:
For patients in whom graft occlusion was suspected,
but who had minimal ischemia (grade I), duplex
scanning was often used for graft imaging. 
Patients with grade II ischemia who underwent 
emergency surgical revascularization did not 
undergo arteriography in all cases.
We now also incorporate duplex ultrasound scan-
ning surveillance during follow-up, but this was not
Fig 1. Primary patency of vein and PTFE grafts. Fig 2. Limb salvage with vein and PTFE grafts.
routinely performed at our center before 1997.
Clinical categories of acute limb ischemia were clas-
sified according to the SVS/ISCVS reporting stan-
dards, as follows: I, viable; II, threatened; III, irre-
versible.7 Patients requiring emergency revascular-
ization were defined as those receiving either
catheter-based or surgical revascularization within
24 hours of admission for treatment of graft 
occlusion.
Descriptive data are presented in terms of means
and SDs. Differences in categoric variables between
groups were compared through use of the χ2 test or
Fisher exact test, as appropriate. Primary graft paten-
cy and limb salvage rates at 48 months were calcu-
lated through use of the Kaplan-Meier method, and
differences between groups were determined
through use of the log-rank test. Statistical analysis
was performed by means of Statistical Package for
the Social Sciences software (version 7.5 for
Windows, SPSS, Inc, Chicago, Ill). Significance was
determined at a P level less than .05.
RESULTS
The mean patient age was similar for the two
groups (SV, 61.4 ± 10.1 years; PTFE, 63.2 ± 9.8
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years; P = .87). Follow-up for the entire group aver-
aged 20.2 ± 19.2 months and ranged from 1 to 76
months. There was a higher percentage of women in
the SV group than in the PTFE group (23% vs 10%;
P = .021). Every patient in the two groups was a
smoker or had a significant history of smoking. The
prevalence of diabetes was similar for the two groups
(SV, 48%; PTFE, 43%; P = .55). The mean age and
distribution of men and women in the two groups
who had graft occlusions was similar to that for the
entire graft group. The mean age of patients with
occluded grafts was 62.0 years for the SV group and
62.7 years for the PTFE group. Of those with
occluded SV grafts, 20.0% were women. In the
occluded PTFE group, 8.3% were women.
Chronic critical ischemia (ischemic rest pain or
tissue loss) was the operative indication in most cases
(SV, 82%; PTFE, 80%; P = .85). The vast majority of
the femoropopliteal bypass graft procedures were
primary operations. Femoropopliteal bypass grafting
was performed as a secondary procedure after previ-
ous failed infrainguinal revascularization in 12% of
the patients in the SV group and 11% of the patients
in the PTFE group (P = .84). The distal anastomo-
sis was performed below the knee in 60% of patients
Table I. Life table for cumulative primary graft patency with SV grafts
No. of patients
Months Entering interval Withdrawn No. of graft occlusions Cumulative patency SE
0 108 36 6 0.933 0.026
6 66 13 7 0.824 0.045
12 46 9 2 0.784 0.051
18 35 6 3 0.710 0.062
24 26 12 0 0.710 0.062
30 14 1 1 0.658 0.076
36 12 6 1 0.584 0.097
42 5 3 0 0.584 0.097
48 2 0 0 0.584 0.097
Table II. Life table for cumulative primary graft patency with PTFE grafts
No. of patients
Months Entering interval Withdrawn No. of graft occlusions Cumulative patency SE
0 81 13 12 0.839 0.043
6 56 8 8 0.710 0.055
12 40 3 7 0.581 0.063
18 30 4 2 0.539 0.065
24 24 3 3 0.467 0.068
30 18 0 3 0.390 0.070
36 15 3 1 0.361 0.071
42 11 1 0 0.361 0.071
48 10 2 1 0.321 0.073
receiving SV grafts but in only 16% of patients
receiving PTFE grafts (P < .001). The preoperative
status of the affected limb was similar for the two
groups, as determined by the ABIs (SV, 0.51 ± 0.29;
PTFE, 0.45 ± 0.20; P = .12) and calculated runoff
scores (SV, 6.0 ± 2.5; PTFE, 5.3 ± 2.8; P = .08).
Clinical outcomes were worse for the group of
patients receiving PTFE grafts than for the group of
patients receiving SV grafts. The incidence of grade
II (limb-threatening) ischemia was 78% after occlu-
sion of PTFE grafts but only 21% after occlusion of
SV grafts (P < .001). Only two patients had grade
III (irreversible) ischemia after graft occlusion, one
in each graft group. The other patients all presented
with grade I ischemia. Emergency revascularization
was required in 28% of those with failed PTFE grafts
but in only 3% of those with occluded VS grafts (P
< .001). Primary patency at 48 months was better
with SV grafts (58%) than with PTFE grafts (32%; P
= .008; Tables I and II and Fig 1). Limb salvage at
48 months was also superior with SV grafts in com-
parison with PTFE grafts (81% vs 56%; P = .019;
Tables III and IV and Fig 2). Major limb amputa-
tion was required in 10% of patients in the SV group
and 28% of patients in the PTFE group (P = .001).
Because outcomes after femoropopliteal bypass
grafting are influenced by preoperative status, we
separately analyzed the degree of ischemia resulting
from graft occlusion according to whether the orig-
inal operative indication was for claudication or
chronic critical ischemia. There were 11 graft occlu-
sions in the 36 patients operated on for claudication
and 45 graft occlusions in the 153 patients operated
on for critical ischemia. For claudicants, the inci-
dence of grade II ischemia after graft occlusion was
0% (0/3) with SV versus 75% (6/8) with PTFE (P
= .06). For critical ischemia, the incidence of grade
II ischemia after graft occlusion was 25% (4/16)
with SV versus 79% (23/29) with PTFE (P = .002).
Other studies have noted differences in outcome
related to the site of the distal anastomosis—specifi-
cally, above-knee versus below-knee. Subanalysis of
the two graft types with respect to location of the
distal anastomosis (above the knee or below the
knee) shows superior primary patency with vein at
both anastomotic locations (Table V). Similarly, the
notable tendency for PTFE graft occlusions to result
in limb-threatening (grade II) ischemia more fre-
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Table III. Cumulative limb salvage with SV grafts
No. of patients
Months Entering interval Withdrawn No. of amputations Cumulative limb salvage SE
0 108 37 4 0.96 0.022
6 67 12 4 0.893 0.037
12 51 10 0 0.893 0.037
18 41 7 2 0.845 0.048
24 32 11 1 0.813 0.056
30 20 4 0 0.813 0.056
36 16 9 0 0.813 0.056
42 7 4 0 0.813 0.056
48 3 1 0 0.813 0.056
Table IV. Cumulative limb salvage with PTFE grafts
No. of patients
Months Entering interval Withdrawn No. of amputations Cumulative limb salvage SE
0 81 13 7 0.906 0.034
6 61 9 5 0.826 0.046
12 47 6 4 0.751 0.055
18 37 6 2 0.702 0.060
24 29 5 2 0.653 0.066
30 22 1 3 0.562 0.075
36 18 5 0 0.562 0.075
42 13 1 0 0.562 0.075
48 12 2 0 0.562 0.075
quently than did vein grafts was demonstrated
regardless of whether the distal anastomosis was
above the knee or below the knee (Table VI).
Because the studies indicating favorable out-
comes with PTFE femoropopliteal bypass grafts
generally include only patients with normal or two-
vessel runoff, we also compared patency and out-
comes on the basis of runoff. The runoff score for
normal or two-vessel runoff (with no significant
stenosis in the patent tibial arteries) would be 4 or
less if calculated according to the SVS/ISCVS stan-
dard method. The primary patency at 36 months for
runoff scores of 4 or less was 53% ± 9%; this com-
pared with 40% ± 8% for runoff scores greater than
4 (P = .67). Similarly, 12 (71%) of the 17 patients
who had graft occlusion and had runoff scores of 4
or less had grade II or greater ischemia at the time
of graft occlusion; this compared with 21 (58%) of
the 36 patients who had higher runoff scores (P =
.63).
Arteriography was obtained in 10 of 19 vein
graft occlusions and 19 of 37 PTFE graft occlusions.
In addition to graft occlusion, obstruction of tibial
outflow was observed as an abnormality in 10 PTFE
graft occlusions (53%) but was seen in only one vein
graft occlusion (10%). Significant inflow stenosis or
occlusion was the most common other abnormality
in vein graft occlusions, observed in four cases
(40%). Inflow disease was seen in two PTFE graft
occlusions (11%). Anastomotic stenosis was
observed after thrombolysis or surgical thrombecto-
my in three vein graft occlusions (30%) and four
PTFE graft occlusions (21%).
DISCUSSION
Our data clearly indicate that graft type (SV vs
PTFE) has a significant influence on clinical out-
come when femoropopliteal bypass grafts occlude.
There was a significantly higher risk of the develop-
ment of limb-threatening ischemia (SVS/ISCVS
grade II) after occlusion of a PTFE femoropopliteal
bypass graft than after occlusion of an SV graft. This
disproportionate outcome in favor of SV was
observed even though there were more infragenicu-
late grafts and more women in this group. Both
groups were well matched with respect to diabetes,
preoperative ABI, and preoperative tibial runoff sta-
tus as measured through use of a standardized grad-
ing system. Although the primary purpose of the
study was to compare the degree of ischemia result-
ing from graft occlusion, we also noted superior pri-
mary patency and limb salvage rates with SV in com-
parison with PTFE.
It is possible that the high prevalence of com-
promised tibial artery runoff (as indicated by high
runoff scores) was a significant factor in determining
the adverse outcomes after femoropopliteal bypass
graft occlusion in our study. However, when the
influence of this factor alone was evaluated, patency
rates and degree of ischemia after graft occlusion
were found not to be significantly different in
patients with good runoff and patients with com-
promised runoff. Given that SV graft failure was not
associated with a high incidence of limb-threatening
ischemia, it would appear that SV is more durable
than PTFE and has superior long-term clinical out-
comes when used for femoropopliteal bypass graft-
ing with compromised tibial runoff. Our data indi-
cate that use of a PTFE graft is a more significant
determinant for poor outcomes than is runoff alone.
Although tibial runoff scores are not provided in
other series that indicate a more favorable outcome
with femoropopliteal PTFE grafts, those series are
generally restricted to claudicants.3,6,8 Such patients
presumably would have better runoff than patients
presenting for limb salvage.
In a recently published prospective study in
which there is a comparison between SV and PTFE
in claudicants undergoing bilateral above-knee
femoropopliteal bypass grafting, AbuRahma et al6
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Table VI. Percentage of graft occlusion resulting in
limb-threatening ischemia (grade II): influence of
site of distal anastomosis
Graft Distal anastomosis Grade II ischemia
SV
Above-knee 11% (1/7)*
Below-knee 30% (3/10)†
PTFE
Above-knee 79% (22/28)*
Below-knee 78% (7/9)†
*P = .001.
†P = .029.
Table V. Primary patency at 36 months: influence
of site of distal anastomosis
Graft Distal anastomosis Primary patency (%)
SV
Above-knee 69
Below-knee 66
PTFE
Above-knee 38
Below-knee 27
P = .01 (SV vs PTFE, adjusted for anastomosis).
treated 43 patients with SV on one leg and PTFE on
the other. All patients had “2- to 3-vessel” runoff. In
that series, the 72-month primary patency (SV, 76%;
PTFE, 68%) and limb salvage (SV, 98%; PTFE, 98%)
were comparable for the two groups. The degree of
ischemia resulting from graft occlusion was not
described. It is difficult to draw comparisons
between that study and our own, given that we
treated so few patients with claudication (15%).
However, even in this small group of claudicants,
the ischemia grade after graft occlusion was worse
with PTFE than with SV.
The results of two other large multicenter stud-
ies comparing SV and PTFE for femoropopliteal
bypass grafting also show results that favor SV, but
they lack sufficient sample size to support a claim for
absolute superiority in all subgroups studied.9,10 In
a multicenter, randomized clinical trial comparing
SV with PTFE in infrainguinal revascularization,
Veith et al9 demonstrated superior patency rates
overall with the use of SV. This difference was espe-
cially profound for those undergoing infrapopliteal
bypass grafting, but even the group that received
femoropopliteal bypass grafts showed higher paten-
cy at 4 years with SV (68%) than with PTFE (47%).
However, when one looks only at above-knee
femoropopliteal bypass grafts, although the 4-year
patency rates are similar to those for the entire group
(61% vs 38%, respectively), the difference does not
achieve statistical significance. Whereas some might
interpret this to mean that there is no clinically sig-
nificant difference, it is more likely that this is a type
II statistical error. In the Veterans Administration
cooperative study in which SV and PTFE were com-
pared with respect to use in infrageniculate bypass
grafts, only 67 of the 596 patients in the study pop-
ulation underwent femoropopliteal (below-knee)
bypass grafting with PTFE; this compared with 159
patients who underwent bypass grafting with vein.10
This discrepancy is probably a result of the study
design, whereby SV was used preferentially, PTFE
being relegated to those with inadequate or unavail-
able SV. At 2 years, the primary patency was 76%
with SV and 64% with PTFE; this failed to achieve
statistical significance (P = .08) and could also rep-
resent a type II error.
Several factors might account for the fact that the
incidence of limb-threatening ischemia was higher
after occlusion of a PTFE graft than after occlusion
of an SV graft. Prosthetic materials are inherently
more thrombogenic than vein. At the time of graft
occlusion, this could cause tibial artery thromboem-
bolism with consequent severe ischemia. We have
insufficient data by which to evaluate this issue in
our study. When prosthetic infrainguinal grafts—in
contrast to vein grafts—have been subjected to rou-
tine ultrasound, some investigators observed no
stenotic graft lesions before graft occlusion.11
Without a gradual change in hemodynamics result-
ing from a progressive graft stenosis, perhaps there is
insufficient time for collaterals to form before pros-
thetic graft occlusion.
Perhaps a more significant factor contributing to
the outcomes with PTFE grafts in our study is that
these were primarily cases in which the choice of
PTFE was “obligatory.” Our preference is to use SV
when it is available and of acceptable quality. In the
study of Veith et al,9 the results with randomized
PTFE were superior to those with obligatory PTFE,
the 4-year patency rates being 47% versus 29%,
respectively (P < .025). The authors commented
that the obligatory PTFE grafts in their study were
often performed in higher-risk circumstances. Our
patients who received PTFE grafts generally had no
SV, either because of prior cardiac or vascular
surgery or because the vein was explored and found
to be of inadequate quality or length. Therefore, our
patients receiving PTFE grafts could also be consid-
ered as higher-risk patients and also would likely be
expected to have worse outcomes than those able to
undergo bypass grafting with SV.
Although arteriography was performed in 51% of
graft occlusions, it is difficult to say whether the
observed abnormalities were the causes or the effects
of the occlusions. This is particularly the case with
respect to abnormal findings in the tibial circulation.
Whereas some of the worsening of the tibial runoff
might represent progression of atherosclerotic
occlusive disease, we cannot rule out the possibility
of thromboembolism. This is particularly of concern
in the PTFE group, in which tibial artery occlusion
was seen in 53% of graft occlusions but in only 10%
of vein graft occlusions. Given the similar degrees of
impaired preoperative runoff in both groups, this
finding does suggest a tendency toward tibial
thromboembolism with PTFE grafts.
The retrospective design and limited follow-up
in our study also mitigate against drawing conclu-
sions regarding the relative superiority of vein 
over PTFE for femoropopliteal bypass grafting.
Adjunctive measures to improve patency with PTFE,
such as postoperative anticoagulation and distal
anastomotic vein cuffs, were not used. Whether the
addition of such measures would have improved the
outcomes with PTFE cannot be determined from
our study. The striking differences in outcome, how-
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ever, argue strongly in favor of the preferential use of
vein over PTFE for femoropopliteal bypass grafting
in patients with compromised tibial runoff scores
and limb salvage as the operative indication.
There were too few claudicants in our study to
evaluate whether PTFE is an acceptable conduit for
femoropopliteal bypass grafting in this circumstance.
The 15% of our patients presenting with claudication
had better outcomes with SV than PTFE, so we con-
tinue to prefer SV in the relatively small number of
claudicants for whom we recommend surgery. Given
the small sample size and the small number of clau-
dicants, we cannot draw strong conclusions in this
regard. When the operative indication is chronic crit-
ical ischemia, our data strongly support the preferen-
tial use of SV over PTFE for femoropopliteal bypass
grafting. Whether this preference for SV can be
extended to arm vein cannot be answered from our
study, but the high incidence of grade II ischemia
after PTFE graft occlusion would seem to support an
all-autogenous policy for limb salvage revasculariza-
tion, even for bypass grafting to the popliteal artery.
We also recommend that future studies evaluating
the relative performance of prosthetic conduits to
vein include standardized runoff scoring systems so
that study groups can be accurately compared.
Perhaps even more important, descriptions of clinical
outcomes in such studies should include objective
classification of the degree of acute limb ischemia
resulting from graft occlusion in addition to the stan-
dard metrics of patency and limb salvage rates.
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DISCUSSION
Dr Stanley O. Snyder (Nashville, Tenn). Thank you,
Jim. As a housekeeping matter, I believe earlier, Paul Bloch
was mentioned as a trainee from East Carolina. I think he
is actually a trainee at Eastern Virginia, where Roger
Gregory is in charge of his training there. If you have been
to Carolina and Virginia, that makes a big difference.
I enjoyed reading this paper and want to congratulate
Dr Jackson on an excellent presentation. The paper
addresses an important clinic point related to lower
extremity revascularization, that is, the outcome differ-
ences following prosthetic versus autogenous graft failure.
My personal anecdotal clinical perspective agrees with Dr
Jackson’s conclusion. However, I am troubled by some of
his data. This retrospective, nonrandomized study mixes
apples, oranges, and tangerines. The clinical conclusion of
more severe ischemia following PTFE graft occlusions
combines above-knee and below-knee bypasses and does
not delineate among ipsilateral saphenous vein, contralat-
eral saphenous vein, or PTFE grafts ranging from 6
through 10 mm in diameter. 
Much of the manuscript deals with increased patency
rates and increased limb salvage with saphenous vein graft
versus PTFE grafts but has some seemingly contrarian data
in that there was no difference in primary patency at 36
months whether the distal anastomosis was done above or
below the knee, and graft occlusion was no more likely to
result in limb-threatening ischemia on the basis of the
location of the distal anastomosis. In addition, neither the
primary patency at 36 months nor severity of occlusion
ischemia was influenced by runoff scores of less than 4
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compared with greater than 4. Interestingly, 11 of 36
(30%) claudicants had graft occlusions, while 45 of 153
(29%) limb salvage patients suffered graft occlusions. 
To me, the real meat of these data lies with the fate of
graft occlusion in claudicants because I believe most of us
would utilize saphenous vein graft for limb salvage situa-
tions when it is available. The numbers are small with only
11 graft occlusions but reveal 0 of 3 saphenous graft
occlusions presenting with grade 2 ischemia, while 6 of 8
PTFE patients with graft occlusions have been converted
from claudicants to limb-threatening ischemic status. 
My questions are many, but I will limit them to three
and a half. You postulated that thrombogenicity of PTFE
and potential tibial thromboembolism with graft occlusion
might be problems, but my question is whether you have
noted angiographic evidence to support the concept that
PTFE occlusion causes thrombosis of the popliteal at the
anastomotic site, while perhaps the vein graft does not. If
so, do you think that adding an autogenous cuff might be
helpful to prevent this? 
Emergency revascularization was defined as receiving
surgical or catheter intervention within 24 hours of admis-
sion. How many grafts, vein versus PTFE, were salvaged
in this manner, and how many had thrombectomy versus
thrombolytic treatment? Did any require fasciotomy?
You have less PTFE grafts than vein patients in the
overall study, but by life table analysis there are more
PTFE grafts at risk at 48 months. Has there been a change
in your more recent clinical practice for utilization of
PTFE versus vein? Would you now ever utilize PTFE for
an above-knee reconstruction in a patient with ipsilateral
saphenous vein available? 
This is a stimulating clinical problem, and I appreciate
the opportunity to discuss it with the society.
Dr Mark R. Jackson. Thank you, Dr Snyder, for your
comments and questions. Concerning your question
regarding the thrombogenicity of PTFE grafts and the
potential for thrombotic occlusion at the level of the
popliteal artery, we have insufficient data to make conclu-
sions. Only one half of the graft occlusions were studied
angiographically. Of those, 53% of PTFE graft occlusions
were associated with worsening of distal runoff, compared
with only 10% with vein graft occlusions. We cannot say
whether this reflects thromboembolism to the tibial circu-
lation, progression of occlusive disease, or some of both.
In terms of the grafts that were salvaged and the
patency restored, we did not formally analyze secondary
patency rates, as our study focused on the ischemic conse-
quences of graft occlusions. In the context of a retrospec-
tive study, we wanted to limit the number of comparisons
between the two graft groups. 
Concerning the slightly higher number of vein grafts
at the onset and the greater number of PTFE grafts at 48
months in the life table, I can offer no real explanation
other than to say that any disparity in this regard is
accounted for in the statistical methods of survival analy-
sis. I do not think any of these slight differences in the
number of patients from each group at any given time are
of any significance. There was no change in our practice
pattern during the time of the study that would have
increased our preference for vein over PTFE.
Regarding your final question, our policy has been to
use saphenous vein whenever possible from infrainguinal
revascularization. In a case where saphenous vein is avail-
able, we would always use it in preference to PTFE for an
above-knee femoropopliteal bypass, even if the operative
indication is claudication. 
Dr William D. Suggs (Bronx, NY). It is an interesting
paper. One thing, which is really a follow-up to Dr Snyder,
when you did your reoperations or at the time that you
reviewed the data, was there any indication about why
these grafts failed, because it may be PTFE and vein grafts
fail in different fashion? If you did thrombectomies, did
you do completion arteriography in the operating room,
and what was the type of operation that was done to sal-
vage these grafts? Anecdotally, I think I would agree that
in my observations when a PTFE graft fails, the patient’s
leg looks worse, but it is difficult to make any real conclu-
sions based on this study unless we have some further
information about why they failed and what was required
to salvage or revascularize the patient’s limb.
Thank you.
Dr Jackson. Those are all important issues. However,
regardless of the outcomes to restore secondary patency
and the angiographic findings at the time of graft failure,
the data presented strongly indicate an advantage with vein
over PTFE. If you look at limb salvage, the number of
amputations, and the percentage of graft occlusions result-
ing in advanced ischemia, the data overwhelmingly favor
the use of vein. Since only one half of failed grafts were
studied angiographically, it is difficult to draw conclusions
regarding the cause of graft occlusion. It seemed that with
PTFE grafts, postocclusion angiograms tended to show
more in the way of compromised tibial runoff than vein
graft occlusions did. However, it is difficult to say whether
this was the cause or the effect of prosthetic graft occlusion.
Dr Theodore J. Bunt (Phoenix, Ariz). It is interesting
when you see science applied to a clinical observation that
most us of make at 3 AM on a Sunday night. Why don’t we
apply a little science to the “why” of this. I would suggest
that perhaps it is a matter of thrombotic threshold veloci-
ty. A vein is going to stay open with very, very remarkably
low flows for whatever failure mode, be it arteriographi-
cally poorer runoff or whatever, so that you probably have
time to build up a good collateral supply. In contrast, a
synthetic graft requires a high velocity flow to maintain
patency. It is for an all-or-none situation, so that when it
occludes you do not have the collaterals and therefore you
have a more ischemic leg. 
Dr Jackson. I agree with you, and in our manuscript we
mention that as one potential mechanism for the differ-
ences in the results.
